- Home
- MRK vs APP Comparison
MRK vs APP Comparison
Compare MRK & APP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRK | APP |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.2B | 228.2B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MRK | APP |
|---|---|---|
| Price | $105.09 | $728.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | $111.93 | ★ $761.94 |
| AVG Volume (30 Days) | ★ 16.4M | 3.8M |
| Earning Date | 02-03-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | 58.08 | ★ 144.05 |
| EPS | 7.56 | ★ 7.98 |
| Revenue | ★ $64,235,000,000.00 | $6,307,450,000.00 |
| Revenue This Year | $1.97 | $22.38 |
| Revenue Next Year | $4.96 | $36.51 |
| P/E Ratio | ★ $13.86 | $91.89 |
| Revenue Growth | 1.68 | ★ 98.48 |
| 52 Week Low | $73.31 | $200.50 |
| 52 Week High | $105.84 | $745.61 |
Technical Indicators
Market Signals| Indicator | MRK | APP |
|---|---|---|
| Relative Strength Index (RSI) | 67.56 | 63.46 |
| Support Level | $96.79 | $654.00 |
| Resistance Level | $100.94 | $738.01 |
| Average True Range (ATR) | 2.50 | 29.56 |
| MACD | 0.03 | 3.98 |
| Stochastic Oscillator | 93.68 | 84.92 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.